• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort
Conclusions In a large real-world population without CVD, people with physician-diagnosed COPD were 25% more likely to have a major CVD event, after adjustment for CVD risk and other factors. This rate is comparable to the rate in people with diabetes and calls for more aggressive CVD primary prevention in the COPD population.
Source: European Respiratory Journal - August 31, 2023 Category: Respiratory Medicine Authors: Maclagan, L. C., Croxford, R., Chu, A., Sin, D. D., Udell, J. A., Lee, D. S., Austin, P. C., Gershon, A. S. Tags: COPD and smoking Original Articles: Tuberculosis and clinical trials Source Type: research

Statement on Tobacco 21 from the European Respiratory Society Tobacco Control Committee
Tobacco consumption is the most significant cause of premature death across the European Union (EU) and is responsible for 700 000 deaths every year. Smokers are more likely than nonsmokers to develop lung cancer, COPD, coronary artery disease, stroke, diabetes, infertility and many other conditions [1]. According to Eurostat, 18.4% of people aged 15 years and over in the EU were daily smokers in 2019 [2]. Across Europe, the minimum age of sale of tobacco products is 18 years as per the obligations of the World Health Organization's Framework Convention on Tobacco Control (WHO FCTC).
Source: European Respiratory Journal - March 23, 2023 Category: Respiratory Medicine Authors: Cox, D. W., Rodriguez, L., Grigg, J., on behalf of the Tobacco Control Committee of the European Respiratory Society Tags: Editorials Source Type: research

Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients
We thank P. Almagro and P. Martinez-Camblor for their interest in our work and for their salient comments. While we agree that there is no universally accepted definition of major adverse cardiovascular event (MACE), the US Food and Drug Administration (FDA) and the European Medicines Agency include nonfatal myocardial infarction and stroke as well as cardiovascular (CV) mortality in their MACE definition [1]. Importantly, this definition includes both haemorrhagic and ischaemic stroke [1–4]. In our study, we followed this classical "three-point" definition of MACE (including haemorrhagic strokes). While this definit...
Source: European Respiratory Journal - March 2, 2023 Category: Respiratory Medicine Authors: Yang, M.-J., Guo, S.-L., Sin, D. D. Tags: Correspondence Source Type: research

Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis
Conclusion Compared with ICS/LABA, dual LAMA/LABA or triple therapy increases cardiovascular risk in patients with COPD. This should be considered in the context of the incremental benefits of these therapies for symptoms and exacerbation rates in patients with COPD, especially in those with a MACE risk of >1% per year.
Source: European Respiratory Journal - February 9, 2023 Category: Respiratory Medicine Authors: Yang, M., Li, Y., Jiang, Y., Guo, S., He, J.-Q., Sin, D. D. Tags: COPD and smoking Original Articles: COPD Source Type: research

COPD and COVID-19: a dangerous association?
Conclusion: COPDs patients are mostly ederly men with comorbidities. The most effective treatment for them was stabilization of comorbidities and conventional oxygen and for the most severe Helmet-CPAP and NIV. In addition, COPD patients had no higher risk of mortality from COVID-19 than individuals without a pre-existing diagnosis of COPD.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Mendez Gonzalez, L., Ferreira, J., Caneiras, C. Tags: 05.02 - Monitoring airway disease Source Type: research

Comorbidities in patients with Obstructive Sleep Apnea syndrome (OSAS) in Reunion Island.
Conclusion: Morbid obesity, hypertension, diabetes, heart disease and respiratory illness are a predictor of severe OSAS in our patients especially snorers.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Omarjee, B., Budhan, S., Kichenin, C., Omarjee, A., Vellin, J. F. Tags: 01.01 - Clinical problems - no related to asthma or COPD Source Type: research

Air leak in Covid 19: experience from a DGH in the UK
Conclusions: Inpatient incidence of PTX and PM is still approximately 1%. Survival is better as overall Covid19 survival improves(direct mortality from air leak approx. 21 %) with mortality due to other factors rather than the air leak.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Aujayeb, A. Tags: 02.01 - Acute critical care Source Type: research

Hospitalizations in OSA patients
Obstructive sleep apnea (OSA) is associated with cardiovascular comorbidities and other chronic diseases, accounting for long-term morbidity, with elevated symptomatic burden and hospitalizations. We aim to study the hospitalizations' causes in OSA patients and its relation to OSA severity and PAP therapy adhesion.This is a retrospective study including 281 hospitalizations corresponding to 200 OSA patients during 2019. Mean age 65 years, 67% were males, and 43,5% (n=87) had severe OSA; 85% patients under PAP; 60,4% (n=102) good adherent patients. Overlap with obesity hypoventilation syndrome (n=7) and COPD (n=48) was noti...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Cancela da Fonseca Ferreira Santos, G. S., Van Zeller, M., Carrico, F., Rodrigues, D., Torres Redondo, M., Drummond, M. Tags: 04.02 - Clinical and epidemiological respiratory sleep medicine Source Type: research

Association of COPD exacerbations with cardiovascular events - a population-based cohort study
Conclusion: Severe exacerbations were associated with increased odds of CV events, which in the majority of patients occurred within 30 days after an exacerbation. This highlights that prevention of exacerbations in patients with COPD and concomitant CVD will improve both respiratory and CV health.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Lokke, A., Lange, P., Ibsen, R., Telg, G., Lykkegaard, J., Hilberg, O. Tags: 06.02 - Occupational and environmental health Source Type: research

Analysis of brain functional connectivity in COPD patients with functional brain MRI
Conclusion: The mechanism of decreased cognitive function or changed mood status in COPD patients is not fully discovered. However, our study showed that alterations in FC of hippocampal lesions might be related with the clinical course of COPD.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Yeo, Y., Rhu, J. T., Jo, H., Jang, S., Choi, J., Park, D. W., Kim, T. Tags: 05.02 - Monitoring airway disease Source Type: research

Impact of cardiovascular disease on in-hospital mortality in patients with COVID-19
Conclusion: COVID-19 patients with CVD comorbidites have a higher risk of in-hospital death. Optimal care and good control of CVD are essential in this patient group.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pencheva Genova, V., Pancheva, R., Stoimenov, B., Manov, E., Kolev, V., Tsrancheva, R., Koshtikova, K., Stoianov, D., Donev, S. Tags: 01.01 - Clinical problems - no related to asthma or COPD Source Type: research

Reduction of lung hyperinflation improves cardiac preload, contractility, and output in emphysema
Conclusions: Reduction of hyperinflation using BLVR with endobronchial valves significantly improved cardiac preload, myocardial contractility, and cardiac output, without changes in pulmonary artery pressures.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: van der Molen, M., Hartman, J., Vanfleteren, L., Kerstjens, H., Van Melle, J., Willems, T., Slebos, D. Tags: 01.02 - Rehabilitation and chronic care Source Type: research

Prevalence of cardiovascular disease in alpha-1 antrypsin deficiency
We present prevalence of CVD from 1158 patients with AATD who are prospectively followed up as part of the Birmingham AATD registry in the UK. All diagnoses come from either central NHS records or patient reports.The prevalence of CVD was as follows: ischaemic heart disease, 5.2%; heart failure, 0.7%, myocardial infarction, 0.9%; stroke, 1.9%; atrial fibrillation 2.4%. Hypertension and hyperlipidaemia were present in 22% and 10.7% of patients respectively. Factors associated with a higher prevalence of CVD include being male (p <0.001), older age (p <0.001), lower KCO (p = 0.008) and presence of hyperlipidaemia ...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Bailey, E., Ellis, P., Turner, A., Ellis, P. Tags: 05.02 - Monitoring airway disease Source Type: research

Local incidence and outcomes of patients with pneumothorax and pneumomediastinum in COVID-19
Conclusions: Inpatient incidence of PTX and PM is 0.98%. Survival is lower (54.5%) but difficult to compare in the presence of frailty and co-morbidities.
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Jackson, K., Aujayeb, A., Aujayeb, A. Tags: Clinical problems Source Type: research

The relationship between eosinophils and reduction in major adverse cardiac events in ETHOS
Conclusion: Overall, there were fewer MACE in ICS-containing therapy groups than GFF. While event numbers were low, benefits of BGF vs GFF on CV death and non-fatal MI related to higher baseline EOS were consistent with the reduction in ACM with increasing EOS previously observed (Martinez, F.J. et al. Am J Respir Crit Care Med 2020. Epub ahead of print).
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bafadhel, M., Rabe, K. F., Singh, D., Jenkins, M., Dorinsky, P., Patel, M. Tags: Airway pharmacology and treatment Source Type: research

Pages: 1  2  3  4  5  6